Previously submitted to: JMIR Research Protocols (no longer under consideration since Feb 25, 2022)
Date Submitted: Apr 24, 2021
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Tofacitinib with Concomitant Therapy for Vitiligo: protocol for a phase II randomized clinical trial
ABSTRACT
Vitiligo is the most common acquired skin depigmentation disorder that affects about 35 million people worldwide. This debilitating disease causes autoimmune destruction of the epidermal melanocytes, forming macules and patches of hypopigmented skin, which causes considerable stigma and a decrease in the quality of life in affected individuals. Narrowband UVB (NB-UVB) is the preferred treatment right now, alone or in combination with immunomodulator drugs. It is not 100% effective and has many adverse effects, as noted in the literature previously. The addition of topical Tofacitinib to the already present therapy has the potential to be a novel treatment with a high level of efficacy for vitiligo. This can significantly improve the quality of life in the millions of people suffering from vitiligo worldwide.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.